



Accelerating Early-Stage Drug Discovery

The o2h Kickstarter Award

ft. The Platinum Partner Programme

A competitive award providing early-stage biotech companies with integrated drug discovery expertise to reach their next milestone.

About The Kickstarter Award

Track Record

8+

Editions across
the globe

45+

Awards provided
so far

\$8.1M+

Invested in
resources

The o2h Kickstarter Awards were first launched in 2022, to provide new therapeutic-focused startups with a 'boost' of chemistry to help achieve initial milestones to enable them to generate the data required to unlock further funding.

To date, we have provided more than 45 Kickstarter awards in the UK, the USA, Australia, Israel and Europe. Many of these companies have continued their growth off the back of this award since joining the program in 2022, and we are proud to have supported them through their early launch.

Benefits



Team

A dedicated team of six FTE synthetic chemists of which two are senior and four are junior chemists



Cost & Duration

Six synthetic chemists at a fraction of the usual price for up to six months



Additional Support

Receive 100 complimentary ADME points and save 20% on Biology FTE



Inventory

Access to a large inventory of chemicals and reagents for synthesis



Scan to know
more about
**The o2h
Kickstarter
competition**



Scan to know
more about
**o2h Kickstarter:
North America**

The o2h Kickstarter: Peptide

Exclusively for Peptide-focused biotech startups

About o2h Kickstarter: Peptide

From Small Molecules to Peptides

The o2h Kickstarter was originally launched to support early-stage biotech companies in accelerating small-molecule drug discovery. Building on strong demand from the biotech community, the programme now extends to peptide therapeutics, with a dedicated edition designed for startups working on peptide-based drug discovery.

This expansion reflects the increasing role of peptides in modern drug discovery and o2h's continued focus on supporting innovation across modalities. The programme is structured to enable progression from early hit identification through to IND-enabling stages, with integrated scientific support to move programmes forward.

How it works?

The Peptide Kickstarter is structured in two stages, giving startups both an initial discovery push and a clear pathway to continued support.

Stage I - Discovery

A defined piece of work to generate early, decision-relevant data

In Stage I, Selected companies will receive:

- 100 peptides synthesis (linear & cyclic)
(at a fraction of the usual price)
- 25 ADME data points
- 20% discount on Biology FTEs
- End-to-end project management



Stage II - Continued Development

Dedicated support to advance your peptide pipeline

Following a successful Stage I, participating companies can continue into Stage II and get:

- Dedicated FTE engagement
(at a fraction of the usual price for upto 6 months)
- 75 additional ADME data points
- 20% discount on Biology FTEs
- Focus on optimisation and further profiling

Programme Benefits *(What you get)*



Peptide Synthesis,
Delivered with
Precision



End-to-End
Chemistry, Built
for Execution



ADME Built
Into the
Programme



Biology
Support, on
Demand

Scan to know more about *The o2h Kickstarter: Peptide*



o2h Kickstarter Winners' Wall

Over the years, we have become a trusted discovery partner to early-stage life science, biotech, and techbio companies, helping them translate innovative ideas into meaningful scientific progress and successful funding outcomes.

Celestial Health

Awen Oncology

Azadyne

OROGEN

SCITHERA

Keystone

5 ALARMBIO

Breakloop

scripta
therapeutics

cosMYC

KUANO

SERINUS

InnoVira

Ternary Tx

ZPrime

GRADIENT®

Permanence Bio

PROTEKT
Therapeutics

Synprox

Jefferson
Thomas Jefferson University

University
of Glasgow

PANNEX
THERAPEUTICS

Atelier Tx
Powering Vitality

SiftrBio

Type6
THERAPEUTICS

MONASH
University

Prota^{ai}

HADO
THERAPEUTICS

Galilei
Biosciences

ORIGAMI
Therapeutics

phrenix
therapeutics

alevin
THERAPEUTICS

ST4TE
therapeutics

Iterion
THERAPEUTICS

TRBO
TR Beta Oncology

HOX
THERAPEUTICS

UCSF
University of California
San Francisco

TRIMTECH
THERAPEUTICS

ADULARIA

PA^m
therapeutics

MOLECULAR GLUE
LABS

serenatis
bio

PSY
THERAPEUTICS

KLYV
Therapeutics

VEIRULENCE

SEVENLESS
THERAPEUTICS

Meet the Kickstarter Winners

Since its launch, the o2h Kickstarter Award has supported innovative biotech companies and academic spinouts from around the world, helping them generate critical scientific data and reach their next milestone.

Winning the o2h Kickstarter Award is a tremendous validation of our team's dedication to solving the MYC problem in cancer. The expertise and collaborative support provided by the o2h team are actively accelerating our hit-to-lead chemistry efforts. This partnership is instrumental in helping us rapidly advance our first-in-class MYC:TRRAP inhibitors from the laboratory toward the clinic, bringing us one step closer to addressing a critical unmet need in oncology.

Dr. Ed Feris
CEO, *cosMYC*



We are deeply grateful to the o2h Kickstarter program for their invaluable support in advancing our small molecule discovery efforts. This partnership has enabled us to expand our compound portfolio and accelerate the lead optimization phase of our lead program. Support from initiatives like o2h Kickstarter plays a crucial role in helping early-stage biotech companies translate scientific innovation into tangible therapeutic opportunities

Ana Montalban
CEO & Co-founder, *Adularia*



The Kickstarter has been pivotal for our development progress. Medchem can be expensive and challenging for early-stage biotechs, but we are now enjoying the momentum this high-quality chemistry programme brings to our lead optimisation. We had heard good things about the Kickstarter before we applied and I am happy to pass on that positivity from our own experience.

Rory Triniman
CEO & Founder, *Veirulence Ltd*



o2h Discovery Platinum Partner

An exclusive benefit that helps you deliver more value to your portfolio

About

Extending the o2h Kickstarter Award to More Biotech Innovators

Through the o2h Kickstarter Award, we've supported 45+ early-stage biotech companies across the UK, USA, Europe, Australia and Israel. Building on its success, we created the Platinum Partner Programme to help even more innovators access specialist drug discovery support during their earliest stages of growth.

The programme enables venture capital firms, venture builders, universities, incubators and technology transfer offices to extend the benefits of the o2h Kickstarter Award directly to eligible companies within their portfolio or ecosystem.

By combining investment and ecosystem support with o2h Discovery's integrated drug discovery expertise, Platinum Partners help founders generate critical scientific data, reduce development risk and accelerate progress towards key technical and fundraising milestones.

Benefits for **Portfolio Companies**



A dedicated team of six synthetic chemists for up to six months to accelerate small molecule discovery programmes



High-purity linear, cyclic and constrained peptide synthesis supports to rapidly expand peptide SAR programmes



100 complimentary ADME points and a 20% discount on biology services



Integrated project management support delivered through o2h Discovery's multi-disciplinary discovery teams

Benefits for **Platinum Partners**



**Add Value
Beyond Capital**



**Strengthen
Portfolio Success**



**Differentiate
Your Ecosystem**



**A Trusted
Discovery Partner**

Our **Platinum Partners**



The o2h Kickstarter Award was created to help early-stage biotech companies access the scientific expertise and discovery capabilities needed to reach their next milestone. Over the past few years, we've had the privilege of supporting more than 45 startups globally, and the Platinum Partner Programme is a natural extension of that journey. We are delighted to welcome all the Platinum Partners and look forward to working together to help more founders accelerate their science and build successful biotechnology companies.



Sunil Shah

Co-founder, o2h Discovery



Amrit Singh Sami

Mercia Ventures investor



Our role is to back exceptional founders and help them overcome the challenges of building breakthrough companies. For many biotech businesses, that means providing access not only to capital but also to the specialist scientific expertise needed to generate robust data and validate their science. By joining the o2h Discovery Platinum Partner Programme, we're strengthening the support available to our life sciences portfolio and giving founders access to another valuable resource as they move from promising science towards commercial success.

We're delighted to become a Platinum Partner of the o2h Kickstarter Programme. Supporting early-stage life science companies is at the heart of what we do at the Milner Institute's Bio-incubator, and this partnership will help more founders access the expertise and resources they need to accelerate their science.

We've already seen the value of the programme through our former resident company, TRIMTECH Therapeutics, which received an o2h Kickstarter Award and worked with the o2h Discovery team to advance its medicinal chemistry programme and targeted protein degradation platform. We look forward to building on that success and helping the next generation of biotech companies translate promising science into new therapies.



Alexandra Huener

*Head of Entrepreneurship,
Milner Therapeutics Institute*



o2h Kickstarter Evolution Across Key Milestones

Therapeutics





Discovery

Pre-clinical

Phase I

Phase II

Phase III

Marketed




Area: Oncology Focus: Prostate Cancer



Area: Metabolic disorders Focus: Obesity



Area: Multi-Therapeutics Focus: Oncology & Neurology



Area: Oncology Focus: Precision oncology



Area: Oncology Focus: Molecular glues (PPIs)

Platform Biotech

Proof of concept

Platform Validation

Pipeline Expansion

Strategic Partnership

Clinical Advancement

Commercial Readiness

Market Leadership



Area: Targeted drug delivery Focus: Tissue-targeted drugs



Area: Drug discovery Focus: Oncology drug discovery

Tech Bio

Proof of concept

Algorithm / Platform Validation

Pipeline Expansion

Strategic Partnership

Clinical Advancement

Commercial Readiness

Market Leadership



Area: Oncology & Immunology Focus: Protein-level disease mapping

Pharma Enablers

Proof of concept

Technology Validation

Early Collaborations

Pharma Partnerships

Commercial Adoption

Industry Standard



Area: Oncology Focus: Oncology drug discovery



Area: Psychiatric & Neurological Disorders Focus: Cognitive Impairment, Schizophrenia



Area: Drug Discovery Focus: Neuroimmune drug discovery





OBN Awards 2025 & 2023

o2h Discovery won the “Best Industry Support Partner of the Year” and “Most Impactful CRO of the Year” awards at the industry-leading OBN Awards at the 2025 & 2023 respectively.



OBN Special Recognition Award for contribution to the life science industry



Seeding New Ideas...

o2h Discovery has a multi-modality integrated drug discovery platform, operating from its state-of-the-art research centres in Cambridge, UK, and Ahmedabad, India. We execute hit-lead-optimisation programmes leading into patent and IND filing with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development.

UK

Mill scitech park
Mill lane
Hauxton
Cambridge
CB22 5HX

USA

CIC Cambridge
1 Broadway
Cambridge
MA 02142

India

Sharmista Research Centre
35, Panchratna Ind. Estate
Changodar, Sarkhej Bavla Road
Ahmedabad
Gujarat 382213

Scan and
Discover More



For more information or to get a quote contact us at: discovery@o2h.com

 o2h-discovery

 o2hgroup

 o2hlife

 o2hlife

 o2h_discovery